Skip to Main content Skip to Navigation
Journal articles

Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile

Abstract : Rifamycins are widely used for treating mycobacterial and staphylococcal infections. Drug-drug interactions (DDI) caused by rifampicin (RIF) are a major issue. We used a model-based approach to predict the magnitude of DDI with RIF and rifabutin (RBT) for 217 cytochrome P450 (CYP) substrates. On average, DDI caused by low-dose RIF were twice as potent as those caused by RBT. Contrary to RIF, RBT appears unlikely to cause severe DDI, even with sensitive CYP substrates.
Complete list of metadata

https://hal.archives-ouvertes.fr/hal-03633663
Contributor : Nolwenn Retiveau Connect in order to contact the contributor
Submitted on : Thursday, April 7, 2022 - 10:33:57 AM
Last modification on : Sunday, September 25, 2022 - 3:56:54 AM

Links full text

Identifiers

Collections

Citation

Vianney Tuloup, Mathilde France, Romain Garreau, Nathalie Bleyzac, Laurent Bourguignon, et al.. Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile. Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 2021, 65 (9), pp.e0104321. ⟨10.1128/AAC.01043-21⟩. ⟨hal-03633663⟩

Share

Metrics

Record views

19